ILIADIN Nasal Spray Solution 0.05 %w/v

Land: Írland

Tungumál: enska

Heimild: HPRA (Health Products Regulatory Authority)

Kauptu það núna

Download Vara einkenni (SPC)
31-05-2024

Virkt innihaldsefni:

OXYMETAZOLINE HYDROCHLORIDE

Fáanlegur frá:

Seven Seas Ltd

Skammtar:

0.05 %w/v

Lyfjaform:

Nasal Spray Solution

Leyfisdagur:

1994-04-01

Vara einkenni

                                PART II
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Iliadin 0.05% w/v Nasal Spray, Solution
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Oxymetazoline Hydrochloride 0.05% w/v.
For excipients, see 6.1.
3 PHARMACEUTICAL FORM
Nasal spray, solution
A clear, colourless solution.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
For the relief of nasal congestion associated with disorder of the upper respiratory tract including infective and allergic
rhinitis, sinusitis, nasopharyngitis and coryza.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Adults and children over 6 years
One spray into each nostril every 8-12 hours.
Intranasally.
4.3 CONTRAINDICATIONS
Use in patients with known hypersensitivity to sympathomimetics.
Use in patients receiving monoamine oxidase inhibitors or within fourteen days of stopping such treatment.
Use in acute coronary disease, cardiac asthma, thyrotoxicosis, hypertension, closed-angle glaucoma or urinary
retention.
Use in children under 6 years of age.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Use with great care in patients suffering from angina and digitalized patients.
This product should be given with care to patients with prostatic enlargement, as it may increase difficulty in
micturition.
Prolonged use may cause rebound congestion and drug induced rhinitis.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 19/12/2006_
_CRN 2031323_
_page number: 1_
Use with caution in diabetic patients as this product may cause an increase in blood sugar.
The physician or pharmacist should reassure himself/herself that sympathomimetic containing preparations are not
simultaneously administered by several routes i.e. orally and topically (nasal, aural and eye preparations).
This pro
                                
                                Lestu allt skjalið
                                
                            

Leitaðu viðvaranir sem tengjast þessari vöru